Cardiovascular

Latest News

MedDiet on table | Image credit: monticellllo - stock.adobe.com
Mediterranean Diet May Optimize Heart Health Among Children, Adolescents

July 25th 2024

Interventions promoting adherence to the Mediterranean diet were associated with cardiometabolic biomarkers in children and adolescents, according to one study.

Patient using a smartwatch | Image Credit: sitthiphong - stock.adobe.com
Wearable Devices Heighten Symptom Monitoring, Health Care Visits for Atrial Fibrillation

July 20th 2024

Aspirin tablets dissolving in water | Imaged credit: Victor Moussa - stock.adobe.com
No Sex Differences Identified in Aspirin Dosing for Secondary Prevention of ASCVD

July 15th 2024

Man investigating money with a magnifying glass | Image Credit: jirsak - stock.adobe.com
Study Finds Higher Health Care Expenditures for Patients With ASCVD, Diabetes

July 11th 2024

Animated heart | Image Credit: - yodiyim - stock.adobe.com
GLP-1s Reduce Cardiovascular Risk Equally in Patients With Overweight, Obesity Regardless of Diabetes

July 4th 2024

Advancements in Population Health Strategies for Cardiovascular Risk Management

Experts discuss how lipoproteins drive atherosclerotic heart disease, review the different guidelines and recommendations on Lp(a) testing, and insights from clinical trials.

Hands holding a heart with a heartbeat on it and the words AJMC Insights
Continuing Medical Education
View All
July 27th 2024

Advances and Best Practices for Managed Care Pharmacists in the Treatment of Heart Failure with Preserved Ejection Fraction

1.0 Credits / Cardiology
July 27th 2024

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
July 27th 2024

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

More News

What We're Reading: Gilead Sued Over PrEP; Seasonal Workers and Medicaid; Preventable Deaths
November 8th 2019

What We're Reading: Gilead Sued Over PrEP; Seasonal Workers and Medicaid; Preventable Deaths

AJMC Staff
HHS takes action against Gilead; a report on fears of seasonal workers in Montana; the latest CDC data on preventable deaths show differences between urban and rural areas.
Dr Danielle Kirkman Explains How Exercise Testing in Patients With CKD Can Improve Care
November 8th 2019

Dr Danielle Kirkman Explains How Exercise Testing in Patients With CKD Can Improve Care

Because exercise capacity is known to be linked with several key outcome measures in patients with chronic kidney disease (CKD), routine exercise testing can help clinicians prescribe individualized exercise interventions, said Danielle Kirkman, PhD, assistant professor at Virginia Commonwealth University.
Cleveland Clinic Announces Top 10 Medical Innovations for 2020
October 25th 2019

Cleveland Clinic Announces Top 10 Medical Innovations for 2020

Matthew Gavidia
Cleveland Clinic announced the top 10 medical innovations for 2020, which details the medical advancements that have the potential power in transforming healthcare in the next year, at a multimedia presentation during the 2019 Medical Innovation Summit.
Study Examines Cardiovascular Disease Impact in Patients With COPD
September 28th 2019

Study Examines Cardiovascular Disease Impact in Patients With COPD

Alison Rodriguez
A recent study investigating the cardiovascular contribution to COPD symptoms and their relationship to a patient's diagnostic status found that patients with suspicious echocardiographic findings were undiagnosed and untreated.
USDA's Topics for the 2020 Dietary Guidelines Committee Exclude Underlying Catalysts for Lifestyle Disease
September 11th 2019

USDA's Topics for the 2020 Dietary Guidelines Committee Exclude Underlying Catalysts for Lifestyle Disease

Matthew Gavidia
Predetermined topics to be discussed by the 2020 dietary guidelines committee failed to mention risks correlated to red meat, processed foods, and appropriate sodium intake, which contribute to the impending epidemic of lifestyle diseases.
People Who Sleep Too Much, or Too Little, at Heightened Risk of Heart Attack
September 5th 2019

People Who Sleep Too Much, or Too Little, at Heightened Risk of Heart Attack

Matthew Gavidia
Less than 6 hours of sleep, as well as durations of longer than 9 hours, are associated with a greater risk of heart attack, according to a new study.
Men With Lower Cardiovascular Fitness at Higher Risk for Migraine, Swedish Study Says
September 4th 2019

Men With Lower Cardiovascular Fitness at Higher Risk for Migraine, Swedish Study Says

Allison Inserro
Young men with a lower level of cardiovascular fitness had a higher risk of developing migraines, according to a recent national, population-based cohort study from Sweden.
Site Logo
September 4th 2019

New Guidelines Supported by Lipid-Lowering Therapy Studies, Indicating Benefit of PCSK9 Inhibitors

Matthew Gavidia
Studies on PCSK9 inhibitors, evolocumab and alirocumab, promote new guidelines for dyslipidemia management through lipid modification to reduce cardiovascular risk.
Dapagliflozin Cuts Risk of CV Death, Worsening of Heart Failure 26%, Whether Diabetes Present or Not
September 1st 2019

Dapagliflozin Cuts Risk of CV Death, Worsening of Heart Failure 26%, Whether Diabetes Present or Not

Mary Caffrey
Dapagliflozin, sold by AstraZeneca as Farxiga, cut the risk of cardiovascular (CV) death and worsening of heart failure (HF) by 26% among patients with reduced ejection fraction alongside standard of care, according to results of a landmark phase 3 study presented Sunday at the European Society of Cardiology 2019 Congress. Results confirmed that the sodium glucose co-transporter 2 (SGLT2) inhibitor, already approved to treat type 2 diabetes (T2D), is just as effective in preventing CV death and HF events in patients who do not have T2D.
Apixaban Shows Lower Rate of Bleeding in Large French Real-World Data Study
September 1st 2019

Apixaban Shows Lower Rate of Bleeding in Large French Real-World Data Study

Mary Caffrey
Data in the real-world study included a large share of patients over the age of 80, who are representative of those doctors see in clinical practice.
FDA Grants Fast Track Designation for Dapagliflozin to Prevent Kidney Failure
August 27th 2019

FDA Grants Fast Track Designation for Dapagliflozin to Prevent Kidney Failure

Matthew Gavidia
Dapagliflozin’s fast track designation follows findings from last year’s DECLARE-TIMI trial, a cardiovascular outcomes trial that showed the drug’s significant impact on delaying the loss of kidney function and reducing hospitalization risk for heart failure.
5 Things to Look for at the European Society of Cardiology 2019 Congress
August 23rd 2019

5 Things to Look for at the European Society of Cardiology 2019 Congress

Mary Caffrey
Studies on anticoagulants and SGLT2 inhibitors, and guidelines for dyslipidemia and more are anticipated at the meeting.
Air Pollution Found to Be Possible Cause of Premature Death Rates
August 22nd 2019

Air Pollution Found to Be Possible Cause of Premature Death Rates

Matthew Gavidia
Researchers found evidence correlating toxic air pollutants to increased respiratory and cardiovascular death rates.
Site Logo
August 19th 2019

Prescription Omega-3 Fatty Acids Effectively Reduce Triglycerides, AHA Says in Advisory

Mary Caffrey
Interest in omega-3 fatty acids have increased since publication of the results of REDUCE-IT.
Improving Heart Health at Age 50 Can Reduce Dementia Risk Later in Life
August 9th 2019

Improving Heart Health at Age 50 Can Reduce Dementia Risk Later in Life

Laura Joszt, MA
People who have better cardiovascular health, as scored by the American Heart Association's Life's Simple 7, at age 50 have a lower risk of developing dementia over the next 25 years, according to a new study.
Rejected, Unfilled PCSK9 Inhibitor Prescriptions Linked to Higher Risk of Cardiovascular Events
July 23rd 2019

Rejected, Unfilled PCSK9 Inhibitor Prescriptions Linked to Higher Risk of Cardiovascular Events

Jaime Rosenberg
Patients were 16% more likely to have a cardiovascular event if their prescription was rejected and 21% more likely to have a cardiovascular event if they did not fill their prescription.
HHS Unveils 5 New Payment Models to Transform Kidney Disease Care
July 10th 2019

HHS Unveils 5 New Payment Models to Transform Kidney Disease Care

Jaime Rosenberg
Following an executive order from President Donald Trump, HHS announced the launch of Advancing American Kidney Health, an initiative to improve the health of the 37 million Americans living with kidney disease, by releasing 5 new payment models.
Site Logo
June 30th 2019

2019 ADA Coverage: Renal Outcomes

Mary Caffrey
Coverage of DECLARE, CARMELINA, and other studies that highlight the connection between diabetes and renal outcomes
Top 5 AJMC® Articles of June 2019
June 30th 2019

Top 5 AJMC® Articles of June 2019

Here are the top 5 articles for the month of June.
Site Logo
June 29th 2019

CREDENCE: First Renal Outcomes Trial Finds Canagliflozin Cuts Risk of Renal Failure, Death; Prompts ADA Updates

Mary Caffrey
Presentations at 2 major scientific conferences showed that the SGLT2 inhibitor cut the risk of renal failure or death by 30% and had renal benefits for patients with and without previous cardiovascular disease.
Site Logo
June 29th 2019

Outcomes Trials Set Stage for Future of Diabetes Management in Patients With Renal Disease

Joseph E. Cruz, PharmD, BCPS Mary Bridgeman, PharmD, BCPS, BCGP
Two doctors of pharmacy review the impact of recent outcomes trials for newer classes of type 2 diabetes therapy.
FDA's Fast Track Designation for Empagliflozin in Heart Failure Points to New Paradigm
June 28th 2019

FDA's Fast Track Designation for Empagliflozin in Heart Failure Points to New Paradigm

Mary Caffrey
The EMPEROR trials could lead to new indications for the SGLT2 inhibitor for patients with and without diabetes.
Site Logo
June 28th 2019

From the Editor-in-Chief: Evolving Role of T2D Therapy, From Secondary to Primary Prevention

Robert A. Gabbay, MD, PhD, FACP
Evidence that newer type 2 diabetes therapies offer cardiovasular and renal benefits offer opportunities for greater collaboration among specialists and more value for patients. Payers must take notice.
Using Real-World Evidence to Understand Disparities, Clinical Inertia
June 18th 2019

Using Real-World Evidence to Understand Disparities, Clinical Inertia

Mary Caffrey
Merck's Center for Observational and Real-World Evidence has spent several years gathering evidence on clinical inertia and is now working on solutions to overcome it at the point of care.
5 Takeaways From the ADA Scientific Sessions
June 14th 2019

5 Takeaways From the ADA Scientific Sessions

Mary Caffrey
There was something for everyone at the American Diabetes Association (ADA) Scientific Sessions, held June 7-11, 2019, in San Francisco, California.
Site Logo
June 12th 2019

More CV, Renal Outcomes at ADA: CREDENCE, CARMELINA, CAROLINA

Mary Caffrey
The final morning session of the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California, featured more cardiovascular and renal results from recent trials involving type 2 diabetes drugs.
Site Logo
June 11th 2019

Highlighting Links Between Kidney, CV Disease in Diabetes

Mary Caffrey
The connections among diabetes, cardiovascular (CV) disease, and kidney failure have been a theme of the 79th Scientific Sessions of the American Diabetes Association, which featured a joint session with the American Society of Nephrology.
This Week in Managed Care: May 31, 2019
May 31st 2019

This Week in Managed Care: May 31, 2019

This week, the top managed care news included the FDA's approval of a $2.1 million gene therapy; a study revealing that the worldwide need for palliative care will nearly double by 2060; the FDA granting priority review to Amarin’s Vascepa for a cardiovascular indication.
Site Logo
May 29th 2019

Combining DPP-4 Inhibitor, SGLT2 Inhibitor for Type 2 Diabetes Cost-Effective Over Time, AJMC® Study Says

A Policy article in the May issue of The American Journal of Managed Care® suggests that sequential addition of SGLT2 inhibitors to DPP-4 inhibitors may be considered cost-effective compared with standard treatment using sulfonylurea and insulin for patients with type 2 diabetes who have difficulty maintaining glycated hemoglobin of seven percent or less on metformin alone.
Heart Disease Topped Reasons for Excess Deaths in Puerto Rico After Hurricane Maria
April 19th 2019

Heart Disease Topped Reasons for Excess Deaths in Puerto Rico After Hurricane Maria

Allison Inserro
Heart disease was the number one reason for “excess deaths” after Hurricane Maria struck Puerto Rico in September 2017.
<12345678910
...
21>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo